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Abstract
Background: The leading causes of death in patients who died with a functioning allograft are cardiovascular diseases, which account for almost 40 percent of all 
deaths in this population. 
Patients and methods: We studied prospectively basic data, hypomagnesaemia HbA1C, renal functions (serum creatinine, eGFR, and urea), and urinalysis. Then 
oral glucose tolerance test was performed as well, and HOMA index was calculated. 
Results: The ratio of patients changed at Minute 120 of the test: there were 22 (37%) patients in the normal group, 26 (43%) patients in the IFG/IGT group, and 
12 (20%) patients in the NODAT group. Regarding basic data, body mass index (p=0.854) did not influence the development of diabetes mellitus significantly. The 
results of laboratory tests showed significant difference in serum Mg level. HbA1C (p=0.009) and HOMA index (p=0.09) were significantly different. Renal function 
parameters, such as serum creatinine (p=0.001) and eGFR (p=0.0001), were also significantly different.
Conclusion: In our clinical study, given the frequency of NODAT and its relationship with cardiovascular risk, correcting hypomagnesemia soon after transplantation 
could translate into a significant decrease in vascular disease, which today is the primary cause of death in kidney transplant recipients.
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Background
New-onset diabetes after transplantation (NODAT) is a serious and 
frequent metabolic complication after renal transplantation [1,2]. This 
entity has been well defined since the publication of the International 
Consensus Guidelines in 2003. The factors contributing to the risk of 
NODAT and the strategies related to modifiable factors, with emphasis 
on practical issues are reviewed in this paper. Recognizing these factors 
may help clinicians to evaluate appropriate prevention strategies 
prospectively to minimize the risk of NODAT. Over the past 50 years, 
the concept of NODAT has evolved in terms of name and definition. 
Before 2003, de novo diabetes that developed after transplantation was 
described in various terms, most frequently as “new onset diabetes 
after transplantation” and suffered from a lack of consensus regarding 
its definition [3]. The most commonly used clinical definition was the 
requirement of insulin for a minimum period post-transplantation 
(often 30 days). This issue was addressed by the development of the 
2003 Consensus Guidelines, developed by the American Diabetes 
Association (ADA) and the World Health Organization (WHO) [4]. A 
diagnosis of NODAT carries a threat to the renal allograft, as well as the 
same short- and long-term implications of type 2 diabetes seen in the 
general population. NODAT usually occurs early after transplantation 
and is usually diagnosed according to the general population 
guidelines. According to these guidelines, diabetes is present if the 
fasting blood glucose level is ≥ 7 mmol/L or if the blood glucose level 
measured 2-h following the oral administration of 75 g glucose, the 
oral glucose tolerance test (OGTT) is ≥11.1 mmol/L. Impaired fasting 
glucose (IFG) is defined as a fasting blood glucose level between 5.6 
mmol/L and 6.9 mmol/L, whereas the normal value (N) for fasting 
blood glucose is <5.6 mmol/L or impaired glucose tolerance (IGT) 
(2-h values in the OGTT) is between 7.8 mmol/L and 11.0 mmol/L. 
OGTT was performed in each patient. Patients with blood glucose 
level ≥ 11.0 mmol/L were selected for the NODAT group. The general 
principle behind standardized NODAT incidence reporting is that the 
diagnostic criteria should reflect what is used in the general population. 
Hopefully, these developments will allow for more consistent reporting 
of NODAT in the future, leading in turn to more precise estimates of 
incidence rates. 
The aim of our study was to compare the risk factors and incidence 
of NODAT and evaluate the body of evidence linking hypomagnesemia 
to clinical consequences in these specific populations, and we focuses 
on the relationship between hypomagnesemia and cardiovascular risk 
in kidney transplant recipients. 
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Material and methods
Our prospective study was performed in the Department of 
Surgery, University of Szeged, Hungary. Patients who had cadaver 
kidney transplantation within at least one year, were above the age 
of 18, had no diabetes mellitus in the past medical history, have not 
received steroid burst therapy, and had no cardiac disease in the past 
medical history were enrolled in the study. A total of 60 patients were 
involved in our study.
Basic data (age, gender, and BMI), time spent in hemodialysis, 
were analyzed. Laboratory tests were performed including serum 
Mg, HbA1C, renal functions (serum creatinine, estimated glomerular 
filtration rate (eGFR), and urea) and urinalysis (total protein and 
glucose secretion). Then OGTT was performed as well, during which 
glucose and insulin levels were measured 0 and 120 minutes after the 
administration of 75 g oral glucose, and then insulin resistance was 
calculated by using the homeostatic model assessment (HOMA) index 
(fasting glucose * fasting glucose / 22.5). Based on the value, the risk of 
insulin resistance (IR) can be determined, if the value is above 2, the 
patient is susceptible to have diabetes mellitus, and in case of a value 
above 4, the patient has IR.
Our study was approved by the Regional Human Biomedical 
Research Ethics Committee of the Albert Szent-Györgyi Clinical 
Center, University of Szeged (Reg. No.: 18/2017-SZTE). Each patient 
was provided comprehensive information regarding the study.
Magnesium physiology
Magnesium (Mg) is the fourth cation of the body and the second 
most prevalent intracellular cation [5]. Approximately half of total body 
Mg is located in bone [6], the remainder being contained in skeletal 
muscles and soft tissues [5]. Extracellular Mg represents only 1% of 
total body Mg [7] and is mostly found in serum with concentrations 
ranging between 0.65 to 1.05 mmol/L [8] and in red blood cells [4]. It is 
present in three different states: ionized Mg (55–70%), protein-bound 
Mg (20–30%), and Mg complexed with anions such as bicarbonate or 
phosphate (5–15%) [5].
Mg homeostasis is mainly dependent on intestinal absorption and 
renal excretion. In the intestine, absorption is modulated by luminal 
Mg concentration, at high concentrations, Mg is regulated by an active 
transcellular transport and passive paracellular diffusion; whereas in 
low concentrations, Mg is absorbed by an active transcellular pathway 
involving a Transient Receptor Potential Melastatin 6 (TRPM6) 
channel expressed on the small intestine cells [5].
Statistical methods
Continuous data were expressed as mean ± standard deviation, 
categorical data were expressed as number of cases and percentages. 
Univariate comparisons were performed by Welch’s ANOVA or Chi-
square test for continuous or categorical variables, respectively. A 
p-value p<0.05 was regarded statistically significant. Statistical software 
IBM SPSS statistics version 24 (64bit) was used.
Results
In our study, there were 30 patients in the normal group, 23 patients 
in the IFG group, and 7 patients in the NODAT at Minute 0 of OGTT. 
The ratio of patients changed at Minute 120 of the test: there were 22 
(37%) patients in the normal group, 26 (43%) patients in the IFG/IGT 
group, and 12 (20%) patients in the NODAT group (Table 1). After 
the transplantation, every patient was administered steroid therapy. 
The risk factors of diabetes were examined to determine which factors 
influence the development of diabetes mellitus significantly. Regarding 
basic data, gender and age did not influence the development of diabetes 
mellitus significantly, although patients with NODAT spent more time 
in HD; the difference was not statistically significant (p=0.662). In 
our study, BMI (26.55 ± 3.84 vs. 28.58 ± 5.26; p=0.854) did not play a 
significant role in the development of NODAT (Table 2). 
The results of laboratory tests showed no significant difference 
in serum magnesium (p=0.001). Renal function parameters, such as 
serum creatinine (p=0.001) and eGFR (p=0.0001) were significantly 
different, while urea (p=0.176) level did not differ significantly between 
groups with different carbohydrate metabolism. The urine total protein 
level was significantly different in the groups (p=0.0001). HbA1C 
(p=0.009) and HOMA index were considered to be the indicator 
of insulin resistance (p=0.09) were significantly different as well. 
Significant difference was found in the total urine protein level between 
the different glucose metabolic groups (Table 3). The analysis of the 
glucose content of the urine showed that there was no glucose in the 
urine except for 4 cases of patients having NODAT, and 3 (+) glucose 
was found in the urine in 2 cases. Patients having normal carbohydrate 
metabolism had no glucose in the urine (p=0.0001).
Discussion
After kidney transplantation, the incidence of NODAT was 
20%. Chronic kidney disease (CKD) is frequently associated with 
hypermagnesaemia, which is usually mild or asymptomatic until 
end-stage renal disease (ESRD). In moderate CKD patients, increased 
fractional excretion of Mg compensates for a decline in renal function, 
providing a stable serum Mg within the normal range Clinical 
manifestations of hypomagnesemia are quite unspecific. Early signs 
include nausea, vomiting, anorexia and weakness [5]. Neuromuscular 
signs can also be present, including numbness, tingling, cramps, 
fasciculation seizures and neuropsychological disorders [5]. Severe 
hypomagnesemia has been associated with cardiac arrhythmia and 
coronary spasm [8-13]. In our clinical study, it was found that the 
recipients basic data were not significantly different concerning 
the onset of NODAT, and the difference in the BMI was also not 
significant, although the average BMI of patients having NODAT was 
higher compared to patients with normal carbohydrate metabolism 
[14-16]. The diabetogenic effect of glucocorticoids, mainly due to 
insulin resistance, is mediated by both impaired insulin-dependent 
glucose uptake in the peripheral tissues and enhanced gluconeogenesis 
in the kidney. We did not investigate the effect of steroids on NODAT 
because all patients received steroids after kidney transplantation. 
Hypomagnesemia is frequently observed after kidney 
transplantation, in part to immunosuppressive regimens including 
calcineurin inhibitors (CNI) that induce Mg urinary waste. 
Minute 0  Minute 120 
N (n=30) N (n=22)
IFG (n=23 IFG/IGT (n= 26)
NODAT (n=7) NODAT (n=12)
22
11
4
1
7
7
Table 1. Results of the OGTT
N-normal; IFG- Impaired fasting glucose; IGT- impaired glucose tolerance; NODAT- new 
onset diabetes after transplantation.
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Hypomagnesemia was observed in 6.6% of patients treated with 
tacrolimus and in 1.5% of patients on cyclosporine [17]. The 
mechanisms leading to hypomagnesemia are not fully understood, 
but it has been shown that CNI induce a down-regulation of renal 
expression of the epidermal growth factor [18] and TRMP6 in the distal 
collecting tubule [19], leading to decreased Mg reabsorption. Sirolimus 
might induce hypomagnesemia through inhibition of Na-K-Cl co-
transporter 2 expression in the thick ascending loop of Henle [20]. 
Renal Mg wasting has been shown to be similar between rats treated 
with sirolimus and those treated with cyclosporine or tacrolimus [21]. 
Many other factors influence Mg levels after kidney transplantation, 
such as post-transplantation volume expansion, metabolic acidosis, 
insulin resistance, decreased gastro-intestinal absorption due to 
diarrhea, low Mg intake and medication such as diuretics or proton 
pump inhibitors [22]. In a Japanese cohort of 728 subjects, lower serum 
Mg was significantly and independently associated with mean intima-
media thickness (p = 0.004) and risk of ≥2 carotid plaques (p = 0.03) 
[23]. Hypomagnesemia was also reported to directly or indirectly affect 
vascular stiffness in the general population [24]. In another study, Mg 
supplementation improved endothelial dysfunction in patients with 
CHD [25].
Hypomagnesemia was reported to develop frequently within the first 
few weeks following transplantation [26], with a serum Mg level nadir 
in the second month post-transplantation [24]. Hypomagnesemia may 
persist for several years after kidney transplantation. In a cohort of 49 
kidney transplant recipients, 22.4% of patients had hypomagnesemia 6 
years after transplantation [20]. As observed in the general population, 
serum Mg levels were inversely correlated with glomerular filtration 
rate [22].
Hypomagnesemia is associated with a higher rate of NODAT but 
not with a reduced risk for graft failure. In regard to the function of the 
allograft, we found that there was significant difference in the serum 
creatinine (p=0.001) and eGFR levels (p=0.0001). NODAT leads to the 
deterioration of renal function and urinary proteinuria (p=0.0001). 
If it is clear that lifestyle modification alone will be insufficient to 
control hyperglycemia, pharmacotherapy targeting glucose metabolism 
should be initiated. In the very early post-transplant phase, when 
corticosteroids are being rapidly tapered, additional pharmacotherapy 
may not be required if the hyperglycemia is mild. The choice between 
insulin and oral hypoglycemic agents depends on the severity, timing, 
and expected duration of hyperglycemia. Insulin therapy is safe, 
particularly when the graft function is not yet established or is unstable.
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